CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 200 target
Drug / intervention
pegylated interferondrug
Likely dose
pegylated interferon 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00132210
NCT00132210Phase 4Completed
CompareCT.gov

Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients

University Hospital, Bonn·interventional·Posted Aug 19, 2005·Updated Oct 21, 2010

In Brief

A Phase 4 clinical trial evaluating pegylated interferon for Hepatitis C and HIV Infections. Completed, enrolled 200 participants across 14 sites.

Detailed Summary

The purpose of this study is to determine whether pegylated interferon therapy is effective to treat acute hepatitis C infection in HIV-coinfected individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, HIV Infections
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 19, 2005
Enrollment StartSep 1, 2002
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 20.9 years ago

Interventions

pegylated interferondrug

Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.